Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.69 USD
Change Today -0.15 / -1.38%
Volume 76.4K
VCYT On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 4:00 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$10.75
Previous Close
$10.84
Day High
$10.87
Day Low
$10.03
52 Week High
06/27/14 - $18.00
52 Week Low
11/14/14 - $6.01
Market Cap
293.3M
Average Volume 10 Days
118.8K
EPS TTM
$-1.38
Shares Outstanding
27.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples

Veracyte, Inc. presented preliminary data demonstrating the ability of the company's molecular classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) using samples obtained through bronchoscopy. The findings suggest the classifier's potential to help thousands of patients avoid invasive, risky and expensive surgery to resolve ambiguity in IPF diagnosis – a frequent challenge for physicians and patients. The data were presented at the American Thoracic Society (ATS) 2015 International Conference in Denver, Colo. The presentation coincides with online publication in TheLancet Respiratory Medicine of an article detailing foundational work and results from an independent test set, which demonstrated classifier performance using patient tissue samples obtained through surgery. The data shared at ATS demonstrate the ability of a Veracyte molecular classifier to distinguish the presence of a specific pathology pattern that is a hallmark of IPF among samples obtained through transbronchial bronchoscopy (TBB). This pathology pattern – whose presence is essential to IPF diagnosis – is often difficult to distinguish without surgery. Using whole-genome data and classifiers trained by histopathology "truth," researchers developed a classifier that could distinguish this pattern with high specificity (92 percent), suggesting its ability to identify and distinguish IPF from other ILDs, including non-specific interstitial pneumonia, emphysema and organizing pneumonia. Each year in the United States and Europe, up to 200,000 patients are suspected of having an ILD, including IPF, which is the most common and most deadly, and is difficult to diagnose.

Veracyte, Inc. - Special Call

To discuss Veracyte NEJM/AEGIS I & II Results

Veracyte, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Revenue Guidance for the Year 2015

Veracyte, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company reported revenue of $11,218,000 against $7,476,000 a year ago. Loss from operations was $7,553,000 against $6,575,000 a year ago. Net loss and comprehensive loss was $7,610,000 or $0.34 per basic and diluted share against $6,674,000 or $0.32 per basic and diluted share a year ago. The company reiterates its 2015 annual revenue guidance of $48 million to $53 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $10.69 USD -0.15

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $27.24 USD +0.13
PDI Inc $1.27 USD +0.02
Response Genetics Inc $0.36 USD +0.0175
Rosetta Genomics Ltd $3.84 USD -0.041
Trovagene Inc $10.93 USD +0.64
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.